Announcements and Notices - [Other - Miscellaneous]

Sihuan Pharmaceutical Holdings Group Ltd. researches and develops cardiocerebral vascular drugs in China. The Company drugs address needs in the areas of anti-infective, metabolism, cardiovascular system, oncology and nervous system.

Voluntary Announcement - Proposed Implementation Of The H Share Full Circulation By Xuanzhu Biopharma

Announcements and Notices - [Other - Business Update]

Voluntary Announcement-Sihuan Pharmaceutical Signs Cooperation Agreement With U.S.-Based Abalone Bio To Jointly Develop A New-Generation Innovative Therapy For Weight Loss And Muscle Gain, Further Deepening Its Layout In The Gpcr Target Field

Voluntary Announcement - Ng-350a Granted Fast Track Designation By The U.S. Fda

Voluntary Announcement
Share Repurchase

Next Day Disclosure Returns - [Share Buyback]

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Voluntary Announcement - Proposed Implementation Of The H Share Full Circulation By Xuanzhu Biopharma

Voluntary Announcement-Sihuan Pharmaceutical Signs Cooperation Agreement With U.S.-Based Abalone Bio To Jointly Develop A New-Generation Innovative Therapy For Weight Loss And Muscle Gain, Further Deepening Its Layout In The Gpcr Target Field

Voluntary Announcement - Ng-350a Granted Fast Track Designation By The U.S. Fda

Voluntary Announcement Share Repurchase

Next Day Disclosure Return